The Journal of Clinical Oncology (JCO) is the primary forum of scientific discourse for the American Society of Clinical Oncology (ASCO). JCO’s goal is to publish the highest quality manuscripts dedicated to clinical oncology, in print and electronic media. Original Reports remain the focus of JCO, but this scientific communication is enhanced by selected Editorials, Review Articles, and other articles that relate to the care of patients with cancer. For manuscript guideline information for all article types, please refer to JCO’s Manuscript Preparation Guidelines. In addition, authors should refer to the International Committee of Medical Journal Editors (ICMJE)’s "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" for additional advice on appropriate manuscript preparation.
MANUSCRIPT CATEGORIES
Original Reports
Original Reports are the primary mode of scientific communication in JCO. The Editor-in-Chief and an Associate Editor generally review Original Reports. Selected manuscripts are also reviewed by at least two external peer reviewers, and, when required, a biostatistician. Comments offered by external reviewers are returned to the author(s) for consideration.
Manuscript acceptance is based on many factors, including the importance of the research to the field of oncology, the originality of the work, the quality of the study, and the priority of the work to JCO and its readership. Authors should focus on accuracy, clarity, and brevity in their presentation, and should avoid lengthy introductions, repetition of data from tables and figures in the text, and unfocused discussions. Extended patient demographic data should be included in a table, not listed within the text.
Original Reports are limited to 3,000 words of body text, excluding the abstract, references, figures, and tables. These articles are limited to six total figures and tables, not counting panels within figures or CONSORT diagrams required for randomized and phase III trials. Additional figures or tables should be labeled "online only" in the legends or next to the titles. All abstracts are strictly limited to 250 words. Titles are to be descriptive, but succinct.
Review Articles
The Editor-in-Chief typically solicits Review Articles. Authors who wish to submit an unsolicited Review should contact the Editor-in-Chief to determine the appropriateness of their Review for publication in JCO. All reviews must be clinically oriented (ie, at least half the review must describe studies that detail human impact, marker effect on prognosis, or clinical trials).
Address all inquiries to Daniel G. Haller, MD, Editor-in-Chief, at jco{at}asco.org. The corresponding author or a co-author, rather than a representative of the authors, should make the inquiry. A detailed explanation of the manuscript concept, along with an outline of the review, must be included in the inquiry. The outline should detail what (if any) specific clinical trials or phase trials would be discussed. Conflict of interest statements for all authors should also be included with the inquiry. Authors may wish to review JCO Conflict of Interest forms before submitting a suitability query.
Review Articles will be reviewed in the same manner as Original Reports. These articles are limited to 4,500 words of body text, excluding the abstract, references, figures, and tables. The Editors also suggest a limit of 150 references.
Editorials and Comments and Controversies
The Editor-in-Chief may solicit an Editorial to accompany an accepted manuscript. Editorials unrelated to a specific article should be submitted to the Comments and Controversies section. Authors who wish to submit unsolicited Comments and Controversies should contact Daniel G. Haller, MD, Editor-in-Chief, at jco{at}asco.org, before submission to determine the appropriateness of the topic for publication in JCO. Editorials should be no more than four to five double-spaced pages.
Special Articles
Special Articles are manuscripts whose content and style do not fall under the categories of Original Reports or Review Articles. These may include, but are not limited to, guidelines, summaries of consensus meetings, and other scholarly communications. Submissions
should be prepared according to JCO's Manuscript Preparation Guidelines.
Biology of Neoplasia
Review Articles for the Biology of Neoplasia series address timely topics in the basic science of cancer. Although these contributions are generally solicited by JCO, proposals are also welcome and should be discussed with Stephen A. Cannistra, MD, Associate Editor, at cannists{at}asco.org. The Editorial Office will send manuscript preparation guidelines for this section of JCO upon solicitation acceptance. Acceptance of Biology of Neoplasia articles is contingent upon satisfactory peer review.
Diagnosis in Oncology
Case reports with high-resolution images, preferably in color, including x-rays or scans of characteristic or classic conditions relevant to oncology, are invited for consideration in the Diagnosis in Oncology section. Each submission should be accompanied by a brief overview describing the case, including a concise literature review. There is no word limit, but the text should not exceed four to five double-spaced pages. Figures must be described within the text (do not use figure legends). If using images of patients, remove all identifying patient information, including names, dates of birth, dates of service, and patient identification codes. Written consent of each patient (or the patient’s legal representative) to publish the image must be uploaded during the submission process as a supplemental file. Consent must be provided even though all of the identifying details are removed from any images and text. If your institution does not have a consent form, please use JCO’s consent form for your Diagnosis in Oncology submission. It is your responsibility to comply with applicable privacy laws and to obtain a HIPAA-compliant patient authorization if the case report or the image includes individually identifiable health information.
The Art of Oncology: When the Tumor Is Not the Target
Art of Oncology articles focus on issues of communication, ethics, and symptom control in the practice of oncology. Text is limited to 3,000 words and generally begins with a short case report to illustrate the discussion, although a case is not mandatory. No abstracts are needed for this section. Authors should consult previously published JCO Art of Oncology pieces to become familiar with the format of these articles.
Correspondence
Correspondence (letters to the Editor) may be in response to a published article, or a short, free-standing piece expressing an opinion. In rare instances, unique cases or observations that would not qualify as an Original Report may be considered. This is not a place to publish studies that have not undergone peer review; if they are of sufficient scientific merit, they should be submitted as an Original Report. If the Correspondence is in response to a published article, the Editor-in-Chief may choose to invite the article's authors to write a Correspondence reply.
Correspondence should be no longer than three double-spaced pages in length. The title page must contain (1) an original succinctly worded title, which is not the same as a previously published JCO article title; (2) author list of no more than 20 names (first name, middle initial, last name); (3) names of the authors’ institutions and an indication of each author’s affiliation; (4) acknowledgments of research support; (5) name, address, e-mail address, and telephone and fax numbers of the corresponding author; and (6) disclaimers, if any.
All accepted Correspondence will be published in the online version of JCO, which is the journal of record. The titles and authors of the Correspondence associated with a particular issue will be listed in that print issue. At the discretion of the Editor-in-Chief, selected Correspondence may also appear in the print version.
[Top]
MANUSCRIPT SUBMISSION REQUIREMENTS
Manuscript Submission Checklist
All new manuscripts should be submitted directly to Daniel G.
Haller, MD, Editor-in-Chief, using the online Manuscript Processing
System.
Upon manuscript submission, corresponding authors must provide unique e-mail addresses for all contributing authors. Receipt of manuscripts will be acknowledged via e-mail. Upon completion of editorial review, the corresponding author will receive notification of the Editors' decision, along with instructions for retrieving reviewers’ comments, as appropriate, via e-mail.
Reports on human experimentation will be reviewed in accordance with the precepts established by the Helsinki Declaration. Such reports must include a statement that human investigations were performed after approval by a local Human Investigations Committee and in accord with an assurance filed with and approved by the Department of Health and Human Services where appropriate. These reports must also include a statement that informed consent was obtained from each participant or each participant’s guardian.
All
manuscripts dealing with recombinant DNA research must include a
description of the physical and biologic containment procedures practiced,
in accord with the
National Institutes of Health Guidelines for
Research Involving Recombinant DNA Molecules.
Manuscripts must contain original material. On the title page, authors should make a statement about the originality of their work and disclose previous presentations, reports, or publications that contain any material that appears in the article. If there is a similar or supplemental publication, the authors should provide a copy for the Editors’ review. This copy should be uploaded as a supplemental file on the Manuscript Processing System. Any previous publication or closely related work should be appropriately cited.
Proprietary drug names are typically given once, at the first mention of the generic drug name in the text, and must accompany the generic drug name. The use of proprietary drug names or devices requires inclusion of the manufacturer’s name and location. Proprietary names will not be published in article titles or abstracts; accepted manuscript titles and abstracts will be modified to contain the generic name only.
[Top]
REVIEW SERIES
In addition to the 30 standard issues of JCO published each year, JCO publishes one Review issue every other month.
JCO encourages proposals of topics and articles by e-mail to specialseries{at}asco.org or through Suggest a Topic under the Special Series section of www.jco.org. Acceptance of any review article is contingent upon satisfactory peer review. The Review Series may contain sections unrelated to the discussion topic These sections include, but are not limited to, Biology of Neoplasia, Diagnosis in Oncology, Art of Oncology, Special Articles, Comments and Controversies, and Correspondence.
[Top]
DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
Authors
In compliance with standards established by the ASCO’s Conflict of Interest Policy (J Clin Oncol 24:519-521, 2006), ASCO’s intent is to promote balance, independence, objectivity, and scientific rigor in all of its editorial policies related to JCO through the disclosure of financial and other interests, and identification and management of potential conflicts. The financial interests or relationships requiring disclosure are outlined in the ASCO Conflict of Interest Policy. All contributors to JCO are required to disclose financial and other relationships with entities that have investment, licensing, or other commercial interests in the subject matter under consideration in their article. These disclosures should include, but are not limited to, relationships with pharmaceutical and biotechnology companies, device manufacturers, or other commercial entities whose products or services are related to the subject matter of the submission.
Disclosures of financial interests or relationships involving the authors must be addressed on the Author Disclosure Declaration form. Each author must complete a declaration form online with each manuscript submission. The corresponding author may complete the form online on behalf of other authors, or authors may complete their own forms and forward them to the corresponding author. This information will be entered as part of the online submission process by the corresponding author, and hard copies of these forms should not be sent to the Editorial Office. Statements regarding financial support of the research must be made on the manuscript title page, and disclosed under question #5 (Research Funding) on the form. This form is available online or upon request from the Editorial Office. The Editorial Office recommends that corresponding authors collect the Author Disclosure Declaration Form from all other authors before starting the formal, online submission. All disclosures will appear in print at the end of all published articles.
Principal Investigator Restrictions
For reports based on clinical trials that began accrual on or after April 29, 2004, the ASCO Conflict of Interest Policy places some restrictions on the financial relationships of Principal Investigators (PIs). If a PI holds any relationships that are restricted by the Policy, his or her manuscript may require an exception to the ASCO Conflict of Interest Policy in order to be considered for publication.
For more information, please see the ASCO Conflict of Interest Policy (J Clin Oncol 24: 519-521, 2006).
Reviewers and Editors
JCO requires all Editors and reviewers to make similar disclosures. Reviewers are asked to make disclosures when accepting a review assignment. Editors’ disclosures are published annually online, whereas reviewers’ disclosures are held in confidence within the Editorial Office.
Additional help regarding ASCO’s Conflict of Interest Policy can be found online at ASCO.org.
[Top]
AUTHORSHIP CONTRIBUTIONS
In accordance with the International Committee of Medical Journal Editors,
each author should have participated sufficiently in the work to take public responsibility for the content. All other contributors who do not meet sufficient criteria for authorship should be noted in the Acknowledgments section. Corresponding authors are responsible for ensuring that all authors have seen and approved the final manuscript prior to submission.
Author Contribution Forms must be filled out and submitted as part of every online submission process. These forms should be forwarded to the corresponding author rather than the Editorial Office. The forms are available online, or upon request from the Editorial Office.
[Top]
CLINICAL TRIALS
Results of clinical studies should be supported by a clear description of the study design, conduct, and analysis methods used to obtain the results.
Reports of phase II studies should include from the protocol a clear definition of the primary end point, the hypothesized value of the primary end point that justified the planned sample size, and a discussion of possible weaknesses, such as comparison to historical controls.
Phase I studies will be well received if they have interesting clinical responses, unusual toxicity that pointed to the mechanism of action of the agents, and important or novel correlative laboratory studies associated with the trials.
[Top]
CLINICAL TRIAL REGISTRATION
Any clinical trial for which patient enrollment begins on or after November 1, 2006, must be registered. Authors will have six months from the first patient enrollment to register the trial, but registration prior to enrollment is recommended. This registration policy applies to prospective, randomized, controlled trials only.
The Editors will follow the ICMJE definition of a clinical trial: "Any research project that prospectively assigns human subjects to intervention and comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. By 'medical intervention' we mean any intervention used to modify a health outcome. This definition includes drugs, surgical procedures, devices, behavioral treatments, process-of-care changes, and the like... a trial must have at least one prospectively assigned concurrent control or comparison group in order to trigger the requirement for registration" (De Angelis CD, Drazen JM, Frizelle FA, et al: Clinical trial registration: A statement from the International Committee of Medical Journal Editors. N Engl J Med 351:1250-1251, 2004).
JCO will accept registration in any public database that meets the World Health Organization's minimal data set. The ICMJE Web site
(FAQs) lists the following registries as fully compliant: www.actr.org.au,
www.clinicaltrials.gov, www.controlled-trials.com,
www.umin.ac.jp/ctr/index.htm, and www.trialregister.nl.
Upon submission, authors are required to provide the registration identification number and the URL for the trial's registry.
[Top]
STATISTICAL GUIDELINES
In the case of randomized clinical trials, authors should follow closely the guidelines of the CONSORT statement. Authors must submit a CONSORT diagram with all randomized studies, but this diagram will not count against the limit of six total figures and tables.
For randomized clinical trials, two-sided P values should be reported. If the trial design was Bayesian, used one-sided P values, or was not based on a standard two-sided test, the primary result and conclusion may be described in terms of the original design, but the two-sided P value of a standard test must also be included. Actual values of all P values should be reported, and not, for example, P >.05. Two digits are sufficient for P > .01.
Differences may be reported in terms of odds ratios or hazard ratios, but there should also be a comparison of an absolute difference of the primary measure (eg, difference in survival at five years or difference in proportions of successes).
When studies report prognostic markers (based on clinical, etiologic, or genetic factors), highest priority will be given to studies for which an algorithm obtained in a training set is applied exactly the same way in the validation set as in the training set (ie, the factors included and the cutoffs must be determined in the training set and applied to each patient in the validation set). Further fine-tuning should be identified clearly as exploratory. Prognostic studies that report the results of an algorithm from the same data that were used to fit the algorithm will have lower priority, but will be enhanced by the inclusion of cross-validation analyses and a clear statement of the limitations of the study.
Reports describing data from multiple studies will be considered to be a true meta-analysis only if the data were analyzed separately and an attempt was made to include study data that were not reported. Studies that apply meta-analytic techniques to published data will have lower priority, and authors should include a discussion of the limitations.
Reports of studies with multiple or secondary end points should address the multiple comparison issues and describe the exploratory nature of the studies.
[Top]
MANUSCRIPT PREPARATION GUIDELINES
Download the Author Disclosure Declaration and Contribution Forms.
Title Page
The first page of the manuscript must contain the following information: (1) succinct title of the report; (2) author list of 20 or fewer names (first name, middle initial, last name); (3) names of each author’s institutions and an indication of each author's affiliation; (4) acknowledgments of research support; (5) name, address, telephone and fax numbers, and e-mail address of the corresponding author; (6) running head of fewer than 65 characters (including spaces); (7) list of where and when the study has been presented in part elsewhere, if applicable; and (8) disclaimers, if any.
Abstract
Abstracts are limited to 250 words and must appear after the title page. Abstracts must be formatted according to the following headings: (1) PURPOSE, (2) PATIENTS AND METHODS (or MATERIALS AND METHODS, METHODS, or similar heading), (3) RESULTS, and (4) CONCLUSION. Authors may use DESIGN instead of PATIENTS AND METHODS in abstracts of Review Articles. Proprietary or trade names may not be used in the title or abstract. Comments and Controversies, Editorials, Correspondence, Art of Oncology, and Diagnosis in Oncology articles do not require abstracts.
Text
The body of the manuscript should be written as concisely as possible and must not exceed the manuscript category word limits described herein. All pages of a submission should be numbered and double spaced. Helvetica and Arial at 12 pt size are the recommended fonts for all text (see Figures section for acceptable fonts for figures). JCO adheres to the style guidelines set forth by the ICMJE.
References
References must be listed and numbered after the body text in the order in which they are cited in the text. They should be double spaced and should appear under the heading “REFERENCES.” Abbreviations of medical periodicals should conform to those used in the latest edition of Index Medicus and on MEDLINE. The "List of Journals Indexed in Index Medicus" includes the latest abbreviations. Inclusive page numbers must be cited in the reference. When a reference is an abstract or supplement, it must be identified as such in parentheses at the end of the reference. Abstract and supplement numbers should be provided, if applicable. When a reference is unpublished data, a manuscript in preparation, or a manuscript submitted but not in press, it should be included in parentheses in the body of the text, and not cited in the reference list. Personal communications should also be listed parenthetically and should contain the first initial and last name of the contact as well as the month and year of the communication. Published manuscripts and manuscripts that have been accepted and are pending publication should be cited in the reference list.
Reference Style
Journal article with one, two, or three authors:
1. Dolan ME, Pegg AE: O6-Benzylguanine and its role in chemotherapy. Clin Cancer Res 8:837-847, 1997
Journal article with more than three authors:
2. Knox S, Hoppe RT, Maloney D, et al: Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. Blood 87:893-899, 1996
Journal article in press (manuscript has been accepted for publication):
3. Scadden DT, Schenkein DP, Bernstein Z, et al: Combined immunotoxin and chemotherapy for AIDS-related non-Hodgkin's lymphoma. Cancer (in press)
Supplement:
4. Brusamolino E, Orlandi E, Morra E, et al: Analysis of long-term results and prognostic factors among 138 patients with advanced Hodgkin's disease treated with the alternating MOPP/ABVD chemotherapy. Ann Oncol 5:S53-S57, 1994 (suppl 2)
Book with a single author:
5. Woodruff R: Symptom Control in Advanced Cancer. Victoria, Australia, Asperula Pty Ltd, 1997, pp 65-69
Book with multiple authors:
6. Iverson C, Flanagin A, Fontanarosa PB, et al: American Medical Association Manual of Style (ed 9). Baltimore, MD, Williams & Wilkins, 1998
Chapter in a multiauthored book with editors:
7. Seykora JT, Elder DE: Common acquired nevi and dysplastic nevi as precursor lesions and risk markers of melanoma, in Kirkwood JM (ed): Molecular Diagnosis and Treatment of Melanoma. New York, NY, Marcel Dekker, 1998, pp 55-86
Abstract:
8. Bardia A, Wang AH, Hartmann LC, et al: Physical activity and risk of postmenopausal breast cancer defined by hormone receptor status and histology: A large prospective cohort study with 18 years of follow up. J Clin Oncol 24:49s, 2006 (suppl; abstr 1002)
9. Kaplan EH, Jones CM, Berger MS: A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab refractory metastatic breast cancer. Proc Am Soc Clin Oncol 22:245, 2003 (abstr 981)
Conference/meeting presentation:
10. Dupont E, Riviere M, Latreille J, et al: Neovastat: An inhibitor of angiogenesis with anti-cancer activity. Presented at the American Association of Cancer Research Special Conference on Angiogenesis and Cancer, Orlando, FL, January 24-28, 1998
Internet resource:
11. Health Care Financing Administration: Bureau of data management and strategy from the 100% MEDPAR inpatient hospital fiscal year 1994: All inpatients by diagnosis related groups, 6/95 update. http://www.hcfa.gov/a1194drg.txt
Digital Object Identifier (DOI):
12. Small EJ, Smith MR, Seaman JJ, et al: Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 10.1200/JCO.2003.05.147
Government Announcement/Publication:
13. Miller BA, Ries CAG, Hankey BF, et al (eds): Cancer Statistics Review: 1973-1989. Bethesda, MD, National Cancer Institute, NIH publication No. 92-2789, 1992
ASCO Educational Book:
14. Benson AB III: Present and future role of prognostic and predictive markers for patients with colorectal cancer. Am Soc Clin Oncol Ed Book 187-190, 2006
Figures
Figures must be cited in the order they appear in the text using Arabic numerals. Figure legends should appear within the document in a separate section just before the references. Figure legends are required for all article types, with the exception of Diagnosis in Oncology articles, and should be double spaced in the manuscript. All relevant and explanatory information extraneous to the actual figure, including figure part labels, footnotes, abbreviations, acronyms, arrows, and levels of magnification in insets, should be defined in the legend text. Figure legends must not exceed 55 words per figure.
JCO prints figures at 1-column, 1.5-column, or 2-column width. One-column figures measure 3.5 inches (8.5 cm), 1.5-column figures measure 5 inches (12.5 cm), and 2-column figures measure 6.75 inches in width (17 cm). Submit figures at 100% size whenever possible.
For first submission of figures, please follow these guidelines:
Images embedded in word processing files will generally, but not always, yield good results. If an image must be embedded in the flow of the document and it is not converting correctly, it is best to create a PDF and submit that instead of the original source file.
Images may be embedded in PowerPoint files, and PowerPoint files may be submitted for conversion, as long as each file contains a single slide. Multi-slide files cannot be converted to a PDF.
For maximum satisfaction with the results of image conversion, try submitting a PDF that you have created. Creation of this file will help you to determine exactly how the image will appear during the peer-review process.
Formats accepted on first submission are .eps, .gif, .tiff, .jpeg, and PowerPoint. Formats that are not supported include the following: any file using OLE (Object Linking and Embedding) technology to display information or embed files, Bitmap (.bmp), PICT (.pict), Excel (.xls), Photoshop (.psd), Canvas (.cnv), CorelDRAW (.cdr), Illustrator (.ai), and locked or encrypted PDFs. Images will be converted to PDFs and appended to the manuscript file. If images are included within the manuscript file, they do not need to be uploaded separately.
For submission of figures upon acceptance, please follow these guidelines:
Submit all line graphs, bar graphs, flow charts, scatter plots, forest plots, diagrams, and gene expressions as vector-based artwork, not bitmapped art (ie, no .bmp, .tiff, .gif, or .jpeg). Vector artwork should be submitted as .eps or PDF files whenever possible, but original documents from applications that are widely available (Adobe Illustrator, Microsoft Word, PowerPoint, or Excel) are also usable. If the graph must be submitted as a bitmap, please submit a 300 dpi .tiff or high-quality .jpeg at 100% scale.
All typeface used within the figures should be 6 pt to 12 pt Univers (Arial or Helvetica are also acceptable), and .eps files with fonts embedded (not converted to paths) are preferred.
Photographs (halftones) must have a minimum resolution of 300 dpi at final size (100% scale). Figure parts should not have figure numbers or letters embedded in the photographs. Labels may be placed on top of the image or set outside of each part. Labels may also be listed in figure legends.
Upon acceptance of a manuscript, a graphic artist will format all figures to JCO style.
Tables
Tables must be cited in the order in which they appear in the text using Arabic numerals. The table’s legend may include any pertinent notes and must include definitions of all abbreviations and acronyms that have been used in the table. Tables submitted with multiple parts will be renumbered.
Appendices/Acknowledgments
Acknowledgments longer than 45 words and all appendices will be published in the online version of JCO. A reference to the availability of the online material will appear in the print version of the article.
Use of English Language
Appropriate use of the English language is a requirement for publication in JCO. Authors who have difficulty
writing in English may seek assistance with grammar and style to improve the clarity of their manuscript. Many companies provide
substantive editing via the Web, including: www.biosciencewriters.com;
www.bostonbioedit.com; www.sciencedocs.com; www.prof-editing.com; www.journalexperts.com; www.bluepencilscience.com and www.stallardediting.com.
Please note that neither ASCO nor JCO takes responsibility for, or endorses, these services. Their use does not guarantee
acceptance of a manuscript for publication.
[Top]
POST-ACCEPTANCE INFORMATION
Copyright Form
Manuscripts will not be published until each author has completed the copyright form.
Upon acceptance of the manuscript, each author will receive an e-mail invitation to sign a statement confirming that the manuscript contains no material for which publication would violate any copyright or other personal or proprietary right of any person or entity. US Federal employees will complete a separate section on the copyright form.
NIH Grantees
The publisher grants the author permission to provide a copy of the accepted manuscript to the National Institutes of Health upon the manuscript's acceptance for publication, with the public release to PubMed Central 12 months after final print publication of the article in JCO.
Page Proofs
Corresponding authors will receive proofs and must carefully review them for data and typesetting errors. When proofs are available for downloading, the corresponding author will receive an e-mail notification with a password and Web address from which PDF proofs can be downloaded and printed. Paper copies will not be sent.
Corrections to proofs must be returned by e-mail, fax, or mail within 48 hours. The corresponding author is responsible for collecting and submitting all author corrections into a single submission. Publication may be delayed if proofs are not returned by the publisher’s deadline. The Editor-in-Chief must approve all major alterations, which may delay publication of the manuscript.
Reprints
An order form showing the cost of reprints accompanies the page proofs so that authors may order reprints before publication. All reprints will be printed in color at no additional charge to the author. Reprints may be ordered after publication, but at a higher cost. In addition to the opportunity to purchase high-quality paper reprints, authors will be given 10 electronic reprints at no charge. These e-prints may be distributed via e-mail to colleagues, regardless of whether the recipients are JCO subscribers.
Permissions
Authors submit manuscripts with the understanding that if accepted, the copyright of the article, including the right to reproduce the article in all forms and media, shall be assigned exclusively to ASCO.
If any portion (eg, a figure or table) of a manuscript submitted for consideration has been published previously, the original source must be acknowledged, and written permission from the copyright holder to reproduce the material must be submitted. Permission is required regardless of authorship or publisher except for documents in the public domain. An outgoing permission template can be found online.
Upon submission, authors are required to upload these permission statements from the copyright holder using the Manuscript Processing System. The accepted manuscript will not be published if the necessary permissions have not been granted.
ASCO will not
refuse any reasonable request for permission to reproduce
any contributions published inJCO. Authors should e-mail requests to permissions{at}asco.org.
[Top]
